Bio-rad Laboratories, INC Form 4 insider transactions

Bio-Rad Laboratories Director Allison Schwartz reported the acquisition of 147 Class A common shares through RSU vesting and the disposition of 55 shares for tax purposes.

Bio-Rad Laboratories EVP James Barry reported the vesting of 602 restricted stock units and the subsequent disposition of 217 shares for tax purposes.

Colleen Corey, EVP of Global Human Resources at Bio-Rad Laboratories, reported the vesting of restricted stock units and subsequent share transactions.

Bio-Rad Laboratories' Chairman and CEO, Norman Schwartz, reported the scheduled vesting of restricted stock units and a subsequent tax-related share disposition.

Bio-Rad Laboratories EVP Eva Anette Engelhardt reported the acquisition of 245 shares of Class A common stock from restricted stock unit vesting and the disposition of 88 shares for tax purposes.

Roop Kalyan Lakkaraju, CFO of Bio-Rad Laboratories, reports the vesting of restricted stock units and a disposition of shares to cover tax obligations.

Courtney C. Enloe, EVP, General Counsel & Secretary of Bio-Rad Laboratories, reports acquisition and disposal of Bio-Rad A Common Stock due to vesting of restricted stock units and tax withholding.

Director Arnold A. Pinkston acquired 308 shares of Bio-Rad Laboratories Class A common stock through the vesting of restricted stock units on April 22, 2025.

Director Melinda Litherland Pei reports acquisition of Bio-Rad Laboratories Class A common stock through vesting of restricted stock units.

Gregory K. Hinckley, a director at Bio-Rad Laboratories, acquired 308 shares of Class A common stock through the vesting of restricted stock units on April 22, 2025.

Jeffrey L. Edwards, a director at Bio-Rad Laboratories, acquired 308 shares of Class A common stock through the vesting of restricted stock units on April 22, 2025.

Michael Crowley, EVP of Global Commercial Operations at Bio-Rad Laboratories, reports the exercise of stock options and subsequent sale of shares on March 14, 2025.

Norman Schwartz, Chairman and CEO of Bio-Rad Laboratories, reports the acquisition of stock options and changes in beneficial ownership of company stock.

Roop Kalyan Lakkaraju, EVP and CFO of Bio-Rad Laboratories, reports the acquisition of stock options and disposition of shares.

James Barry, EVP and President of LSG at Bio-Rad Laboratories, acquired 2,918 non-qualified stock options on March 3, 2025, vesting over four years.

Courtney C. Enloe, EVP, General Counsel & Secretary of Bio-Rad Laboratories, reports acquisition of shares via employee stock purchase plan and stock options.

Eva Anette Engelhardt, EVP and President of CDG at Bio-Rad Laboratories, acquired stock options on March 3, 2025.

EVP Colleen Corey of Bio-Rad Laboratories reports the acquisition of stock options in a recent SEC Form 4 filing.

Sedat Evran, EVP of Global Supply Chain at Bio-Rad Laboratories, acquired 2,918 non-qualified stock options on March 3, 2025.

Jonathan P. DiVincenzo, President & COO of Bio-Rad Laboratories, acquired stock options on March 3, 2025, according to a Form 4 filing.

Jonathan P. DiVincenzo, President & COO of Bio-Rad Laboratories, reports the acquisition of 7,478 restricted stock units.

Sedat Evran, EVP of Global Supply Chain at Bio-Rad Laboratories, reports the vesting of restricted stock units and related tax withholding.

Eva Anette Engelhardt, EVP and President of CDG at Bio-Rad Laboratories, acquired 4,608 restricted stock units on September 6, 2024, vesting over four years.

Courtney C. Enloe, EVP, General Counsel & Secretary of Bio-Rad Laboratories, acquired 3,072 restricted stock units on September 6, 2024.

Roop Kalyan Lakkaraju, EVP and CFO of Bio-Rad Laboratories, reports the acquisition of 6,143 restricted stock units.

Sedat Evran, EVP of Global Supply Chain at Bio-Rad Laboratories, acquired 3,456 restricted stock units on September 6, 2024, which vest over four years.

Norman Schwartz, Chairman and CEO of Bio-Rad Laboratories, reports changes in his beneficial ownership of company stock, including the disposal of Bio-Rad B Common Stock and acquisition of Restricted Stock Units.

Andrew J. Last, EVP and Chief Operating Officer of Bio-Rad Laboratories, reported the acquisition and disposal of Bio-Rad A Common Stock on September 6, 2024.

Director Allison Schwartz reports acquisition of 369 restricted stock units in Bio-Rad Laboratories, vesting over four years.

Colleen Corey, EVP of Global Human Resources at Bio-Rad Laboratories, reported the acquisition of 2,304 restricted stock units.